Cardiovascular disease is the leading cause of premature death in systemic lupus erythematosus, a population already burdened by inflammation, immune dysregulation, and polypharmacy. If a medication already prescribed for lupus control can meaningfully reduce that cardiovascular toll — simply by being taken consistently — the implications for disease management are substantial.
This prospective longitudinal study from the Wisconsin SLE cohort followed 248 adults over one year, tracking both whole-blood hydroxychloroquine (HCQ) levels as a marker of recent exposure and the proportion of days covered (PDC) as a measure of long-term adherence. Ten-year atherosclerotic cardiovascular disease (ASCVD) risk was calculated at baseline and twelve months using the validated PREVENT calculator. Patients with very low HCQ blood concentrations (below 200 ng/mL) combined with poor long-term adherence (PDC under 80%) carried a mean predicted 10-year ASCVD risk of 6.6% at baseline — roughly 2.1 percentage points higher than better-adherent peers. Those who remained in or migrated into low-exposure categories over the follow-up year sustained the highest cardiovascular risk at the one-year mark.
HCQ's cardioprotective mechanisms are plausible and partially characterized: the drug modulates lipid profiles, reduces platelet aggregation, dampens inflammatory cytokine activity, and may attenuate endothelial dysfunction — all relevant to the accelerated atherosclerosis that defines lupus-related cardiovascular risk. What makes this study analytically notable is the dual-exposure framework, distinguishing recent adherence from longitudinal patterns, which adds granularity beyond simple blood-level snapshots. That said, the study is observational and single-cohort, limiting causal inference and generalizability across more diverse SLE populations. The PREVENT calculator, while validated, was not specifically developed for autoimmune disease populations. The finding is nonetheless clinically coherent and adds prospective longitudinal weight to what has largely been cross-sectional evidence. For rheumatology practice, it reinforces that HCQ blood-level monitoring paired with adherence optimization is not merely about lupus disease control — it may carry measurable cardiovascular benefit.